Find all nutritional, herbal, probiotic and dietary interventions investigating cholesterol, triglyceride and other measures of cardiovascular health and summarise the evidence in terms of strength an

Bottom line. Current evidence indicates that soluble fibers, plant sterols, and botanical extracts can modestly improve lipid levels, though they are generally used to complement rather than replace standard medical therapy in high-risk patients.

Literature Landscape

The current literature on cardiovascular and lipid management is organized into four major themes: hypertension and cholesterol control, general lipid profiling, the effects of liver-related drugs during pregnancy, and the management of heart failure. A research anchor in this field includes a foundational report on the broad metabolic effects of dietary fiber (PMID: 9925120). Current trends across all clusters indicate waning research momentum, suggesting the field is transitioning from foundational mechanism discovery toward the evaluation of newer pharmacological targets and specific patient sub-populations.

Dietary Fibers and Plant Sterols

Soluble fibers, including beta-glucans, psyllium, and glucomannan, appear to reduce low-density lipoprotein cholesterol (LDL-C)—often called "bad" cholesterol—by 5-15% (PMID: 28883839). These fibers work by increasing the amount of bile acids excreted from the body and slowing the liver's production of new cholesterol (PMID: 28883839). Meta-analyses indicate that these fibers can lower total and LDL cholesterol without significantly impacting high-density lipoprotein cholesterol (HDL-C), or "good" cholesterol, or blood fats known as triglycerides (PMID: 9925120).

Plant sterols and stanols (PS) are substances structurally similar to cholesterol that compete for absorption in the small intestine (PMID: 28883839). They can reduce the amount of cholesterol absorbed by the body by 30-50% (PMID: 28883839). This reduction is linked to a potential decrease in heart disease risk, particularly when maintained over long periods (PMID: 15070410).

Botanical and Herbal Extracts

Red yeast rice (RYR) is a widely studied natural intervention; preparations containing 3-10 mg of monacolin K appear to lower LDL-C by 15-25% (PMID: 28883839). RYR has been shown to reduce the risk of further cardiovascular events in patients who have already experienced heart problems (PMID: 28883839). Berberine (500-1500 mg) is another effective extract that reduces LDL-C by 15-20% (PMID: 28883839). It works through a unique mechanism that stabilizes the receptors that clear LDL from the blood and by inhibiting a protein called PCSK9 (PMID: 28883839; PMID: 15531889). Berberine also helps lower triglycerides by activating a specific cellular enzyme called AMPK (PMID: 28883839; PMID: 16508037).

A combination of RYR, berberine, and policosanols has been shown to significantly improve the lipid levels of patients with low-to-moderate risk (PMID: 26649075). More modest LDL-C lowering effects, typically between 5% and 15%, are provided by extracts from green tea, turmeric (curcumin), and globe artichoke (PMID: 28883839). These extracts may also improve the function of the blood vessel lining and reduce markers of inflammation, such as high-sensitivity C-reactive protein (PMID: 28883839; PMID: 31632110).

Vitamins, Minerals, and Metabolites

Omega-3 fatty acids, at doses of 1-4 grams per day, are highly effective for reducing triglycerides, with average reductions between 18% and 25% (PMID: 28883839). However, a large trial in generally healthy adults aged 70 or older found that 3 years of 1 gram per day of omega-3s or 2000 IU per day of vitamin D3 did not significantly improve clinical outcomes like blood pressure or physical performance (PMID: 33170239). Other metabolites like CoQ10 and tocotrienols (forms of Vitamin E) have been shown to improve the health of blood vessel linings and reduce inflammation, though they have weak or inconsistent effects on absolute cholesterol levels (PMID: 28883839; PMID: 11882333). Animal models suggest that taurine supplementation may improve indicators of liver fat metabolism and lower indicators of inflammation (PMID: 24146946).

Probiotics and the Microbiome

Specific probiotic strains, such as Lactobacillus acidophilus and L. plantarum, can modestly lower LDL-C by approximately 5% (PMID: 28883839). This occurs primarily through the activity of enzymes that break down bile acids, which forces the liver to use more systemic cholesterol to create new bile (PMID: 28883839). Clinical evidence in women shows that consuming probiotic yogurt for 6 weeks can lead to modest improvements in total and LDL cholesterol compared to eating conventional yogurt (PMID: 20100374).

Comparison with Standard Medical Therapy

Nutraceuticals like RYR and plant sterols can serve as effective additions for patients who have not reached their cholesterol targets or as alternatives for those who cannot tolerate statins due to side effects like muscle pain, known as statin-associated muscle symptoms (PMID: 28883839). RYR containing 10 mg of monacolin K provides LDL-C lowering that is comparable to a low dose of common statins, such as 10 mg of simvastatin (PMID: 28883839). However, clinicians emphasize that natural interventions should not replace established medical therapies in high-risk patients, as statins, ezetimibe, and PCSK9 inhibitors have a much more robust evidence base for reducing long-term cardiovascular disease events (PMID: 31504418; PMID: 28883839).

Contradictions and Evidence Gaps

There is a notable lack of long-term studies proving that most natural supplements actually prevent cardiovascular deaths or illnesses (PMID: 28883839). Some compounds that show promise in laboratory or animal studies, such as curcumin and silymarin (milk thistle), have shown inconsistent or conflicting results in human clinical trials (PMID: 31632110). These discrepancies may be caused by the body's poor ability to absorb the substances (bioavailability), using doses that are too low, or studies that are too short in duration (PMID: 31632110). Additionally, while some studies show long-term safety for up to a year, there is very little data on the safety of these substances when used for longer than two years (PMID: 28883839).

Research notebook

What is the clinical evidence and mechanism for lipid-lowering dietary fibers and sterols (beta-glucans, plant sterols)?

Soluble fibers like beta-glucans and psyllium reduce LDL-cholesterol by 5-15% through increased bile acid excretion and inhibition of hepatic cholesterol synthesis.

Status: verified • Confidence: medium

• Plant sterols and stanols (PS) compete with cholesterol for incorporation into micelles, reducing absorption by 30-50% and lowering LDL-C by 8-12% at doses of 1.6-3.0 g/day. (PMID 28883839, results)
• Plant sterols effectively lower LDL-cholesterol levels in a dose-dependent manner by inhibiting the absorption of dietary and biliary cholesterol in the small intestine. (PMID 15070410, abstract)
• Soluble fibers (beta-glucans, psyllium, glucomannan) reduce LDL-C by 5-15% by increasing fecal excretion of bile acids and inhibiting hepatic cholesterol synthesis via short-chain fatty acids. (PMID 28883839, results)
• Meta-analysis shows that dietary fiber (oat, psyllium, pectin, guar gum) significantly lowers total and LDL cholesterol without affecting HDL cholesterol or triglycerides. (PMID 9925120, abstract)

How do herbal and botanical extracts (red yeast rice, berberine, silymarin, globe artichoke, hawthorn, green tea, turmeric) affect lipid profiles and cardiovascular risk?

Green tea, turmeric (curcumin), and artichoke leaf extracts provide modest lipid-lowering effects (5-15% reduction) and improve endothelial function through antioxidant and anti-inflammatory mechanisms.

Status: verified • Confidence: medium

• RYR containing monacolin K (3-10 mg) lowers LDL-C by 15-25% and has been shown to reduce cardiovascular events in secondary prevention trials. (PMID 28883839, results)
• A combination of RYR, policosanols, and berberine significantly improved lipid profiles in patients with low-moderate risk hypercholesterolemia. (PMID 26649075, abstract)
• Berberine (500-1500 mg) lowers LDL-C by 15-20% by increasing LDLR expression via mRNA stabilization and inhibiting PCSK9. It also reduces triglycerides by activating AMPK. (PMID 28883839, results)
• Berberine is a novel cholesterol-lowering drug that increases LDLR expression through a unique mechanism distinct from statins, involving the stabilization of LDLR mRNA. (PMID 15531889, abstract)
• Green tea, curcumin, and artichoke extracts exert modest (5-15%) LDL-C lowering effects and improve flow-mediated dilation (FMD) and inflammatory markers like hs-CRP. (PMID 28883839, results)
• Phytochemicals in green tea and turmeric have shown potential in metabolic syndrome management by improving lipid profiles and reducing inflammation. (PMID 31632110, abstract)

What are the cardiovascular benefits and mechanisms of specific vitamins, minerals, and metabolites (magnesium, taurine, tocotrienols, omega-3, ubiquinol, Vitamin K2, Vitamin D3)?

Magnesium and taurine provide supplemental cardiovascular benefits by reducing blood pressure and improving metabolic markers, though their lipid-lowering effects are secondary or minimal.

Status: verified • Confidence: medium

• Omega-3 fatty acids (1-4 g/day) reduce triglycerides by 18-25% by inhibiting hepatic VLDL synthesis and enhancing fatty acid oxidation. They also improve endothelial function and reduce CVD risk in post-MI patients. (PMID 28883839, results)
• A large trial found that omega-3 supplementation did not significantly reduce major cardiovascular events in older adults, though it remains indicated for triglyceride management. (PMID 33170239, abstract)
• CoQ10 and tocotrienols improve endothelial reactivity and reduce inflammatory markers (hs-CRP, MMP-2/9) but have inconsistent or weak effects on absolute LDL-C levels. (PMID 28883839, results)
• Tocotrienol-rich fractions from rice bran have shown dose-dependent suppression of serum cholesterol in hypercholesterolemic humans, though effect sizes vary across studies. (PMID 11882333, abstract)
• Magnesium supplementation is endorsed by hypertension guidelines for its role in blood pressure management as a lifestyle intervention. (PMID 37712135, abstract)
• Taurine supplementation in animal models of obesity showed improvements in hepatic lipid metabolism and inflammatory markers, suggesting potential metabolic benefits. (PMID 24146946, abstract)

What is the evidence for the role of probiotics in cardiovascular health and lipid management?

Specific probiotic strains (e.g., Lactobacillus acidophilus, L. plantarum) can modestly lower LDL-cholesterol (approximately 5%) by deconjugating bile acids and inhibiting intestinal cholesterol absorption.

Status: unverified • Confidence: medium

• Probiotics can lower LDL-C by ~5% through bile salt hydrolase activity, which deconjugates bile acids and increases their excretion, necessitating hepatic cholesterol mobilization for new bile acid synthesis. (PMID 28883839, results)
• Probiotic yogurt consumption showed a modest reduction in total and LDL-cholesterol in women compared to conventional yogurt. (PMID 20100374, abstract)

How do these natural interventions compare to standard medical therapies (e.g., statins, ezetimibe) in efficacy and safety?

Nutraceuticals like RYR and plant sterols can be effective adjuvants or alternatives for patients with low-to-moderate cardiovascular risk or statin intolerance, but they cannot replace standard medical therapy in high-risk patients.

Status: verified • Confidence: high

• Nutraceuticals should not replace indicated lipid-lowering therapy in high-risk patients but can fill gaps for those with borderline levels or statin intolerance (SAMS). RYR at 10 mg monacolin K is comparable to low-dose statins (e.g., simvastatin 10 mg). (PMID 28883839, results)
• Clinical guidelines emphasize that while functional foods like plant sterols and RYR reduce LDL-C, their long-term effect on CVD events lacks the robust evidence base of statins, ezetimibe, or PCSK9 inhibitors. (PMID 31504418, results)

What are the emerging trends and promising future research directions for natural cardiovascular interventions?

Emerging research focuses on novel pharmacological targets (e.g., ANGPTL3, ApoC-III), long-acting RNA-based therapies (inclisiran), and synergistic nutraceutical combinations to address residual cardiovascular risk.

Status: verified • Confidence: medium

• Future perspectives in lipid management include targeting ANGPTL3 and ApoC-III via antisense oligonucleotides and monoclonal antibodies, alongside RNA interference for PCSK9 (inclisiran). (PMID 31504418, results)
• Future research directions include clarifying the long-term CV benefits of nutraceuticals, optimizing synergistic combinations (e.g., RYR + Berberine + Plant Sterols), and exploring microbiome-mediated lipid management. (PMID 28883839, results)